Growing Body of Evidence Highlights Potential Applications for Liquid Biopsy in Clinical Practice
Erin JungmeyerDuring a lecture at NACLC 22, Dr. Christian Rolfo illustrated how ctDNA could be used to monitor progression and inform treatment decisions. Read more
When Perfect is the Enemy of Good: Investigators Compare Rigorous Clinical Trial Data to Real-World Experience
Kamya Sankar, MD+more
Using a real-world cohort of US veterans, researchers examine the effectiveness of durvalumab consolidation in unresectable stage III NSCLC. Read more
NACLC 22 Educational Session Explores the Rationale for Immune Checkpoint Inhibition
Erin JungmeyerDuring IASLC’s North America Conference on Lung Cancer, MD Anderson’s Dr. Tina Cascone reviewed the evidence for neoadjuvant and adjuvant therapy in NSCLC. Read more
Structure-Based Classification System for EGFR Mutations May Help Clinicians Personalize Treatments for More Patients
Xiuning Le, MD, PhD+more
Grouping mutations based on their likelihood of response to specific drug types in future EGFR TKI trials may eventually help physicians tailor treatments for patients with atypical mutations. Read more
More Robust Tools Needed to Predict who will Respond to Immune Checkpoint Inhibitors
Andrew McKenzie, PhDInvestigators at Sarah Cannon look to next-generation sequencing for molecular signatures that may correlate with response. Read more
Real-World Data from Taiwan Shows Stage Shift Has Improved Lung Cancer Survival Rates
Pan-Chyr Yang, MD, PhD+more
Researchers say increased screening of at-risk populations, including those who have never smoked, may improve survival more than any other strategy. Read more
Using Comparative Effectiveness Data Based on Non-Randomized Study Designs to Support Regulatory, Reimbursement Decision-Making
Sreeram Ramagopalan, PhDStudy provides evidence to support the potential role of real-world data in consideration of technologies where only single-arm trial data exists. Read more
In Measuring Outcomes, a Longer-Term View May be Needed
Mark Hennon, MD+more
When publicly reported patient outcomes emerge, the data available to patients should paint the most complete picture possible. Read more
Alternative Dosing Strategies for Immune Checkpoint Inhibitors
Michiel Zietse, MSc+more
Combining fixed- and weight-based dosing approaches may reduce costs without compromising efficacy. Read more
Panel Explores Emerging Treatments and Sequencing Strategies for Patients with Advanced NSCLCs Driven by Rare Oncogenes
Beth Fand IncollingoDuring the 2022 European Lung Cancer Congress, experts reviewed evidence on drugs targeting MET exon 14 skipping mutations and RET, HER2, and BRAF alterations. Read more